RESEARCH ARTICLE

The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis

Chunli Zhang1-2☯, Xiaohua Chen3☯, Lu Li4, Ying Zhou1*, Chao Wang5*, Shuxun Hou1,2*

1 Institute of Orthopedics, the First Affiliated Hospital of Chinese People’s Liberation Army General Hospital, Beijing, China, 2 Medical School of Chinese People’s Liberation Army, Beijing, China, 3 Department of Laboratory Medicine, No 161 Hospital of People’s Liberation Army, Wuhan, China, 4 Key Laboratory of Environment and Health, Ministry of Education & Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 5 Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

☯ These authors contributed equally to this work.
* kendyzhouying@163.com (YZ), wangchao75@163.com (CW), ortho304@163.com (SH)

Abstract

Background
Telomeres are essential for chromosomal integrity and stability. Shortened telomere length (TL) has been associated with risk of cancers and aging-related diseases. Several studies have explored associations between TL and cancer prognosis, but the results are conflicting.

Methods
Prospective studies on the relationship between TL and cancer survival were identified by a search of PubMed up to May 25, 2015. There were no restrictions on the cancer type or DNA source. The quality of the included studies was assessed using the Newcastle-Ottawa Scale. Meta-analysis approaches were conducted to determine pooled relative risks and 95% confidence intervals.

Results
Thirty-three articles containing forty-five independent studies were ultimately involved in our meta-analysis, of which twenty-seven were about overall cancer survival and eighteen were about cancer progression. Short TL was associated with increased cancer mortality risk (RR = 1.30, 95%CI: 1.06–1.59) and poor cancer progression (RR = 1.44, 95%CI: 1.10–1.88), both with high levels of heterogeneity ($I^2 = 83.5\%$, $P = 0.012$ for overall survival and $I^2 = 75.4\%$, $P = 0.008$ for progression). TL was an independent predictor of overall cancer survival and progression in chronic lymphocytic leukemia. Besides, short telomeres were also associated with increased colorectal cancer mortality and decreased overall survival of esophageal cancer, but not in other cancers. Cancer progression was associated with TL in
Asian and America populations and short TL predicted poor cancer survival in older populations. Compared with tumor tissue cells, TL in blood lymphocyte cells was better for prediction. In addition, the associations remained significant when restricted to studies with adjustments for age, with larger sample sizes, measuring TL using southern blotting or estimating risk effects by hazard ratios.

**Conclusion**

Short TL demonstrated a significant association with poor cancer survival, suggesting the potential prognostic significance of TL. Additional large well-designed studies are needed to confirm our findings.

**Introduction**

Telomeres are specialized structures that adorn the ends of eukaryotic chromosomes. Human telomeres comprise short tandem repeats 5’-TTAGGG-3’ and telomere related proteins [1]. It is generally believed that telomeres protect chromosomes from degradation and end-to-end fusion, thus playing an essential role in maintaining chromosomal integrity [2]. In normal human somatic cells, telomeres ranges from 9 to 15 kb initially, and shrink by about 50–200 nucleotides per replication cycle [3]. With continuous shortening, telomeres reach a critical length and consequently the deficient telomere triggers irreversible cell cycle arrest known as cellular senescence, apoptosis and even malignance [4].

Telomere structure is sensitive to a wide spectrum of endogenous and environmental factors such as aging, oxidative stress, unhealthy lifestyle and genotoxic stress [5]. These factors jointly influence the cell fate jointly by modifying telomere length (TL) and structure and leading to disease occurrence. Therefore, TL has been proposed as an integrated biomarker for age and a general risk for age-associated diseases [6]. In particular, it has been reported that in mice models excessive telomere shortening contributes to the evolution of genome instability and thus is involved in cancer formation [7–9]. Accordingly, telomeres in human tumor cells were usually shorter than those in the surrounding normal tissue cells [10, 11].

Several studies have explored the correlations between TL and the risk of different cancers. Moreover, systematic reviews and meta-analyses have confirmed inverse associations of TL with cancer morbidity and other aging-related diseases [12–15]. There are also some prospective studies which examined the impact of TL on cancer survival, but the results are conflicting. For example, a recent report indicated that patients with shorter leukocyte TL had significantly worse overall survival and relapse-free survival than those with longer TL in colorectal cancer [16]. Conversely, Garcia-Aranda et al. found that long TL predicted poor colorectal cancer prognosis [17]. Svenson et al. showed that longer TL was associated with increased breast cancer death risk [18], while some other studies failed to observe a significant association [19–21]. These apparent discrepancies suggest that individual studies may be under powered for the detection of true associations due to limited sample sizes. Given this reason, we conducted a meta-analysis to provide a comprehensive assessment of the relationship between TL and cancer death and disease progression.
Methods

Search strategy

We performed a systematic literature search on PubMed electronic database using the following key words: “telomere length”, “cancer” or “carcinoma” or “tumor”, and “survival” or “prognosis” or “mortality”. The last search was updated on May 25, 2015. To identify more pertinent publications, the reference lists of selected articles were also hand searched.

Study selection

Studies which met the following criteria were eligible: (1). Study evaluated the relationship between TL and cancer survival with a prospective design. (2). Using long (or longest) TL as reference, the study provided relative risks (RRs) or hazard ratios (HRs) with 95% confidence intervals (CIs) for shorter (or shortest) TL. Alternatively, sufficient information was available to estimate the above effect sizes. (3). Participants must be newly diagnosed cancer patients. Therefore, studies focused on cancer-specific mortality in general population were excluded. (4). Studies analyzing the associations of TL with all-cause mortality were rejected because we were focused on cancer survival. If the same study was reported more than once, we selected the most recently published one to avoid repetition. In addition, if an article presented results for several different cohort studies we considered them as independent studies. There were no restrictions on cancer type, DNA source or measurement of TL.

Data extraction

For each eligible study, we used a standardized abstraction form to extract the following information: first author, year of publication, mean or middle point of follow-up time, region, cancer type, number of participants, measurement method for TL, DNA source, whether adjusted for age, TL classification (dichotomy, trichotomy or quartile), endpoint (death or disease progression), RRs or HRs with corresponding 95% CIs for short TL versus long TL, and adjusted confounders. If possible, the effect size with the largest degree of adjustment for potential confounders was included.

Quality assessment

The Newcastle Ottawa Scale (NOS) was used to assess the quality of the included studies [22]. Briefly, each study was judged on three broad dimensions: the selection of the study subjects, the comparability of the study populations and the ascertainment of the outcome of interest in cohort studies. Overall, each study received a total score from zero to nine stars, and a study was considered of high quality if it scored seven or more stars.

Statistical analysis

To enrich our work, we not only analyzed the association of TL with cancer overall survival, but also extended the outcomes to cancer progression events, including treatment-free survival, relapse-free survival, disease-free survival and progression-free survival. For the vast majority of the studies included in this meta-analysis, a median value (or other cut-point) of the TL in cancer patients divided all subjects into two groups: a short TL group and a long TL group. The association between the TL and cancer survival was examined by RRs or HRs and corresponding 95% CIs with the long telomere as the reference. However, a few studies reported associations for tertile or quartile categories of TL. In these cases, we chose the effect size for shortest telomere versus longest telomere, with the group of longest telomere as the reference. Finally, we combined HRs with RRs and reported RRs as summary effect sizes for simplicity.
The between-study heterogeneity was assessed by the Cochran $Q$ test and $I^2$ statistic and was considered significant if $P < 0.05$ for Cochran $Q$ test or $I^2 > 50\%$. When significant heterogeneity was detected, values from different studies were combined using a random-effects model; otherwise, a fixed-effects model was utilized. To evaluate the effect of TL on survival in patients with different cancer types, we detected this relationship by cancer type independently if it was reported in at least two studies. Meta-regression was performed to find the source of heterogeneity. Firstly, an empty regression was run to estimate the baseline value for $\tau^2$. Then, univariate meta-regressions were successively conducted with grouping variables. If $\tau^2$ was significantly reduced after one variable entered into the model, then this variable was responsible for heterogeneity among the studies. In subgroup analysis, the included studies were stratified by the following items: age of diagnosis, follow-up time, area, cancer category, whether adjusted for age, number of subjects, technique for TL determination, DNA source, number of divided TL groups and risk type. Sensitivity analyses were performed by excluding each study individually and recalculating the pooled effect sizes. Additionally, we investigated publication bias by funnel plot and Egger’s regression tests.

All analyses were conducted using Stata 10.0. All $P$ values were two-sided and a $P < 0.05$ was considered statistically significant.

Results

Characteristics of included studies

As shown in Fig 1, the literature search strategy initially identified 739 articles. After scanning the titles and abstracts, sixty-nine publications remained for further investigation. Among these articles, thirty-six were excluded due to the following reasons: normal population as subjects but not cancer patients ($n = 5$), study on other diseases or disease therapy ($n = 4$), concerned with TL change or other intermediate phenotypes ($n = 17$), data not available for survival analysis ($n = 9$), or duplicated studies ($n = 1$). There were ten publications which researched both overall survival and disease progression, and one publication collected the results of two independent cohorts, thus they were considered separately. Finally, thirty-three articles containing forty-five independent studies were enrolled in our meta-analysis, of which twenty-seven studies were about cancer overall survival and eighteen studies were about cancer...
progression [16–21, 23–49]. The essential information for the included studies is listed in Table 1 and S1 Table. Diverse cancers were involved, including chronic lymphocytic leukemia, breast cancer, colorectal cancer, bladder cancer and many others. However, because there were too many cancer types, we combined these cancers into several major categories, including gastrointestinal cancer, female cancer, urinary cancer, neurological cancer, blood cancer and others, in meta-regression and subgroup analysis. The sources of DNA included blood (n = 21), tumor tissue (n = 18), mixed (n = 1) and unclear (n = 1). Quantitative polymerase chain reaction (qPCR) was the primary method for TL determination, while southern blot and fluorescence in situ hybridization-based (FISH) approaches were also utilized. Additionally, European was the predominant ethnic group reported, followed by American and Asian. Thirty-eight out of the forty-five included studies categorized TL into two groups: a long TL group and a short TL group. All the studies except one [44] were of high quality based on our NOS quality assessment.

Results of meta-analysis

We observed consistent significant associations between TL and cancer overall survival and progression (Figs 2 and 3). The combined risk for cancer overall survival was 1.30 (95% CI: 1.06–1.59) for short TL compared with long TL. However, these studies displayed high heterogeneity (I² = 83.5%, P = 0.012). Short TL was also associated with cancer progression risk: the pooled risk estimate was 1.44 (95% CI: 1.10–1.88), with significant heterogeneity (I² = 75.4%, P = 0.008). However, this association varied across different cancer types (Fig 4). Short TL predicted poor overall survival and cancer progression in chronic lymphocytic leukemia, the combined RRs were 2.68 (95% CI: 1.70–4.23, P = 0.000, I² = 52.9%) and 1.78 (95% CI: 1.25–2.54, P = 0.002, I² = 61.9%), respectively. Short telomeres were also associated with increased colorectal cancer mortality (RR = 2.54, 95% CI: 1.73–3.72, P = 0.000, I² = 0.0%) and decreased overall survival of esophageal cancer (RR = 0.61, 95% CI: 0.45–0.82, P = 0.001, I² = 0.0%). We failed to find significant associations in other cancers.

Meta-regression and subgroup analyses

Meta-regression and subgroup analyses were performed to explore the potential source of between-study heterogeneities. No subgroup presented in our study could perfectly explain the heterogeneous results for overall cancer survival (Table 2). However, when cancers were grouped into site-specific types, the results showed that short telomere was associated with increased death risk in blood cancer (RR = 2.68, 95% CI: 1.70–4.24, P = 0.000, I² = 52.9%), but not other cancer categories. We also found the relationship between TL and overall cancer survival was significant in studies with older subjects (RR = 1.60, 95% CI: 1.11–2.30, P = 0.011, I² = 88.0%), with adjustment for age (RR = 1.39, 95% CI: 1.09–1.78, P = 0.008, I² = 76.6%), measuring TL using southern blot (RR = 2.34, 95% CI: 1.05–5.20, P = 0.038, I² = 86.9%), using blood samples (RR = 1.34, 95% CI: 1.05–1.70, P = 0.018, I² = 85.9%), dividing TL into two groups (RR = 1.30, 95% CI: 1.02–1.65, P = 0.035, I² = 84.6%) or four groups (RR = 1.88, 95% CI: 1.03–3.43, P = 0.040, I² = 91.7%) and estimating risk effects by HRs (RR = 1.43, 95% CI: 1.10–1.86, P = 0.008, I² = 84.9%). As for cancer progression, sample size may explain part of the heterogeneity, with tau² robustly reduced from 0.337 to 0.215 (P = 0.022) in a univariate meta-regression model. Additionally, tau² was reduced from 0.337 to 0.265 when stratified by risk type, suggesting that statistical method might also introduce heterogeneity (P = 0.050). Accordingly, only studies with larger sample size or reporting HRs remained significant after stratification, with RRs being 1.93 (95% CI: 1.58–2.36, P = 0.000, I² = 38.7%) and 1.69 (95% CI: 1.36–2.11, P = 0.000, I² = 60.1%), respectively (Table 3).
| First author | Year | Cancer          | Follow-up time | Region  | Method       | Sample     | TL groups | Risk (95% CI)   |
|-------------|------|-----------------|----------------|---------|--------------|------------|-----------|-----------------|
| Overall survival |      |                 |                |         |              |            |           |                 |
| Zhang       | 2014 | ESCC            | 38 months      | Asia    | qPCR         | tumor tissue | 2         | 0.69 (0.46–1.02) |
| Duggan      | 2014 | breast cancer   | 11.2 years     | America | qPCR         | blood      | 2         | 1.32 (0.98–1.79) |
| Chen        | 2014 | colorectal cancer | 28 months     | Asia    | qPCR         | blood      | 2         | 2.43 (1.53–3.45) |
| Russo       | 2014 | bladder cancer  | 16.3 years     | Europe  | qPCR         | blood      | 2         | 3.90 (1.70–9.10) |
| Weischer    | 2013 | multiple cancers | unclear        | Europe  | qPCR         | blood      | 4         | 1.31 (1.14–1.52) |
| Lötsh       | 2013 | glioblastoma    | 14.2 months    | Europe  | qPCR         | tumor tissue | 2         | 0.93 (0.57–1.52) |
| Mansouri    | 2013 | CLL             | 83 months      | Europe  | qPCR         | blood      | 2         | 2.42 (1.40–4.19) |
| Heaphy      | 2013 | prostate cancer | 13.2 years     | America | FISH         | tumor tissue | 2         | 2.94 (1.35–6.39) |
| Jeon        | 2014 | NSCLC           | unclear        | Asia    | qPCR         | tumor tissue | 4         | 2.43 (1.02–5.79) |
| Liu         | 2012 | HCC             | 16.7 months    | Asia    | qPCR         | blood      | 2         | 0.49 (0.35–0.68) |
| Lu          | 2011 | breast cancer   | 86 months      | Europe  | qPCR         | tumor tissue | 2         | 1.20 (0.71–2.04) |
| Willeit     | 2011 | multiple cancers | unclear        | Europe  | qPCR         | blood      | 3         | 1.52 (1.05–2.21) |
| Rossi       | 2009 | CLL             | 32 months      | Europe  | Southern blot | blood     | 2         | 13.31 (3.76–47.05) |
| Rossi       | 2009 | CLL             | 54.2 months    | Europe  | Southern blot | blood     | 2         | 1.91 (1.04–3.52) |
| Svenson     | 2009 | ccRCC           | 24 months      | Europe  | qPCR         | blood      | 2         | 0.33 (0.15–0.77) |
| Svenson     | 2008 | breast cancer   | unclear        | Europe  | qPCR         | blood      | 2         | 0.34 (0.16–0.75) |
| Bechter     | 1998 | CLL             | 23 months      | Europe  | Southern blot | tumor tissue | 4         | 3.27 (1.23–8.66) |
| Kotsopoulos | 2014 | ovarian cancer  | unclear        | America | qPCR         | blood      | 2         | 1.14 (0.91–1.30) |
| Lin         | 2014 | bladder cancer  | 21.6 months    | America | qPCR         | blood      | 2         | 1.25 (0.82–1.90) |
| Shen        | 2012 | breast cancer   | 8 years        | America | qPCR         | blood      | 2         | 0.87 (0.68–1.13) |
| Hultdin     | 2003 | CLL             | 82 months      | Europe  | Southern blot | combined  | 2         | 2.00 (1.21–3.30) |
| Gertler     | 2004 | colorectal cancer | 76 months     | Europe  | Southern blot | tumor tissue | 2         | 3.56 (1.18–10.76) |
| Gertler     | 2008 | Barrett carcinoma | 79 months     | Europe  | Southern blot | tumor tissue | 2         | 0.53 (0.34–0.84) |
| Pezzolo     | 2015 | NB tumors       | 43.2 months    | Europe  | FISH         | tumor tissue | 3         | 0.17 (0.05–0.53) |
| Chen        | 2015 | glioma          | 24 months      | Asia    | qPCR         | blood      | 2         | 1.39 (1.04–1.86) |
| Qu          | 2015 | gastric cancer  | 42 months      | Asia    | qPCR         | blood      | 2         | 2.78 (1.24–4.48) |
| Boscolo-Rizzo| 2015 | HNSCC          | 24 months      | Europe  | qPCR         | tumor tissue | 2         | 1.20 (0.67–2.14) |
| Disease/Progression/Treatment free survival |      |                 |                |         |              |            |           |                 |
| Spanoudakis | 2011 | MPN             | 63 months      | Europe  | FISH         | tumor tissue | 2         | 0.48 (0.28–0.83) |
| Chen        | 2014 | colorectal cancer | 28 months     | Asia    | qPCR         | blood      | 2         | 2.26 (1.35–3.23) |
| Mansouri    | 2013 | CLL             | 84 months      | Europe  | qPCR         | blood      | 2         | 1.93 (1.16–3.19) |
| Heaphy      | 2013 | prostate cancer | 13.2 years     | America | FISH         | tumor tissue | 2         | 2.43 (1.24–4.76) |
| Jeon        | 2014 | NSCLC           | unclear        | Asia    | qPCR         | tumor tissue | 4         | 1.56 (0.76–3.20) |
| Lu          | 2011 | breast cancer   | 86 months      | Europe  | qPCR         | tumor tissue | 2         | 1.20 (0.76–1.89) |
| Rossi       | 2009 | CLL             | 32 months      | Europe  | Southern blot | blood     | 2         | 2.02 (1.33–3.07) |
| Rossi       | 2009 | CLL             | 54.2 months    | Europe  | Southern blot | blood     | 2         | 2.14 (1.32–3.47) |
| Rampazzo    | 2012 | CLL             | 45 months      | Europe  | qPCR         | blood      | 2         | 2.97 (1.74–5.09) |
| Borsén      | 2011 | CLL             | 58 months      | Europe  | qPCR         | tumor tissue | 2         | 0.36 (0.12–1.06) |
| Yan         | 2013 | AML             | 12 months      | Asia    | Southern blot | tumor tissue | 2         | 2.46 (1.38–4.38) |
| Roos        | 2008 | CLL             | 52 months      | Europe  | qPCR         | unclear    | 2         | 1.47 (0.88–2.45) |
| Garcia-Aranda| 2006 | colorectal cancer | 43.8 months | Europe  | Southern blot | tumor tissue | 2         | 0.10 (0.01–0.74) |
| Pezzolo     | 2015 | NB tumors       | 43.2 months    | Europe  | FISH         | tumor tissue | 3         | 0.25 (0.10–0.63) |
| Augustine   | 2015 | colorectal cancer | 21 months     | America | qPCR         | tumor tissue | 2         | 1.82 (1.08–3.65) |
| Chen        | 2015 | glioma          | 24 months      | Asia    | qPCR         | blood      | 2         | 1.41 (1.06–1.87) |
| Qu          | 2015 | gastric cancer  | 42 months      | Asia    | qPCR         | blood      | 2         | 2.64 (1.19–4.55) |

(Continued)
In addition, short telomere predicted poor outcomes in cancer progression in studies with older participants (RR = 1.86, 95% CI: 1.37–2.54, $P = 0.000$, $I^2 = 51.1\%$), with Asian or American subjects (for Asian: RR = 1.90, 95% CI: 1.44–2.51, $P = 0.000$, $I^2 = 37.6\%$; for American: RR = 2.07, 95% CI: 1.32–3.26, $P = 0.002$, $I^2 = 0.0\%$), with adjustment for age (RR = 1.69, 95% CI: 1.38–2.08, $P = 0.000$, $I^2 = 20.1\%$), measuring TL using southern blot or qPCR (for southern blot: RR = 1.79, 95% CI: 1.04–3.10, $P = 0.037$, $I^2 = 67.8\%$; for qPCR: RR = 1.64, 95% CI: 1.30–2.07, $P = 0.000$, $I^2 = 52.4\%$), using blood samples (RR = 2.01, 95% CI: 1.64–2.47, $P = 0.000$, $I^2 = 31.1\%$) and dichotomizing TL (RR = 1.56, 95% CI: 1.21–2.02, $P = 0.001$, $I^2 = 72.0\%$).

Table 1. (Continued)

| First author     | Year | Cancer         | Follow-up time | Region | Method | Sample          | TL groups | Risk (95% CI) |
|------------------|------|----------------|----------------|--------|--------|-----------------|-----------|---------------|
| Boscolo-Rizzo    | 2015 | HNSCC          | 24 months      | Europe | qPCR   | tumor tissue    | 2         | 1.15 (0.59–2.25) |

$^a$: Mean or middle point of follow-up time.

Abbreviations: ESCC: esophageal squamous cell carcinoma, CLL: chronic lymphocytic leukemia, NSCLC: non-small-cell lung cancer, HCC: hepatocellular carcinoma, ccRCC: clear cell renal cell carcinoma, MPN: myeloproliferative neoplasms, AML: acute myelocytic leukemia, NB: neuroblastoma, HNSCC: head and neck squamous cell carcinoma, qPCR: quantitative polymerase chain reaction, FISH: fluorescence in situ hybridization-based approach.

doi:10.1371/journal.pone.0133174.t001

Fig 2. Forest plot for association between telomere length and cancer overall survival. Results are presented for random effects models.

doi:10.1371/journal.pone.0133174.g002
Fig 3. Forest plot for association between telomere length and cancer progression. Disease-free survival, treatment-free survival, progression-free survival and relapse-free survival were involved. Results are presented for random effects models.

doi:10.1371/journal.pone.0133174.g003

Fig 4. The association between telomere length and cancer prognosis in different cancers. Only cancer types included at least two studies are presented.

doi:10.1371/journal.pone.0133174.g004
Sensitivity analysis and publication bias

Sensitivity analysis was performed subsequently. However, removing each study individually did not alter the relationships between TL and cancer outcomes materially (S2 Table).
pooled RRs for overall survival range from 1.24 (95% CI: 1.02–1.52) to 1.36 (95% CI: 1.12–1.65), and cancer progression from 1.37 (95% CI: 1.05–1.81) to 1.57 (95% CI: 1.23–2.01), while both of the relevant between-study heterogeneities remained significant. A funnel plot was drawn for twenty-seven studies which focused on overall cancer survival, and results showed no obvious asymmetry (Fig 5). On the basis of Egger’s regression test and Begg’s test, there was no evidence of publication bias among these studies (P = 0.431 for Egger’s test, P = 0.144 for Begg’s test).

Table 3. Subgroup analysis of telomere length and cancer progression.

| Subgroup     | No. of studies | Risk (95% CI)     | P      | I²   | P for metareg |
|--------------|----------------|-------------------|--------|------|--------------|
| Age          |                |                   |        |      | 0.609        |
| < = 60 years | 8              | 1.27 (0.86–1.89)  | 0.223  | 74.90%|              |
| > 60 years   | 8              | 1.86 (1.37–2.54)  | 0.000  | 51.10%|              |
| Unclear      | 2              | 1.05 (0.23–4.81)  | 0.951  | 94.70%|              |
| Follow-up time|               |                   |        |      | 0.990        |
| < 45 months  | 9              | 1.45 (0.99–2.13)  | 0.056  | 75.60%|              |
| >= 45 months | 8              | 1.40 (0.89–2.18)  | 0.146  | 80.40%|              |
| Region       |                |                   |        |      | 0.256        |
| Asia         | 5              | 1.90 (1.44–2.51)  | 0.000  | 37.60%|              |
| America      | 2              | 2.07 (1.32–3.26)  | 0.002  | 0.00% |              |
| Europe       | 11             | 1.08 (0.70–1.66)  | 0.739  | 82.50%|              |
| Cancer type  |                |                   |        |      | 0.640        |
| GCs          | 4              | 1.71 (0.90–3.25)  | 0.104  | 69.40%|              |
| Blood cancers| 8              | 1.51 (0.97–2.34)  | 0.066  | 80.80%|              |
| NCs          | 2              | 0.63 (0.12–3.41)  | 0.591  | 91.90%|              |
| Whether adjusted for age| |                   |        |      | 0.254        |
| Yes          | 7              | 1.69 (1.38–2.08)  | 0.000  | 20.10%|              |
| No           | 11             | 1.14 (0.71–1.82)  | 0.589  | 83.60%|              |
| Number of participants| |                   |        |      | 0.022        |
| < 170        | 9              | 0.87 (0.51–1.50)  | 0.612  | 80.40%|              |
| >= 170       | 9              | 1.93 (1.58–2.36)  | 0.000  | 38.70%|              |
| Method       |                |                   |        |      | 0.210        |
| qPCR         | 11             | 1.64 (1.30–2.07)  | 0.000  | 52.40%|              |
| FISH         | 3              | 0.68 (0.19–2.40)  | 0.546  | 89.90%|              |
| Southern blot| 4              | 1.79 (1.04–3.10)  | 0.037  | 67.80%|              |
| DNA source   |                |                   |        |      | 0.099        |
| Blood        | 7              | 2.01 (1.64–2.47)  | 0.000  | 31.10%|              |
| Tumor tissue | 10             | 0.95 (0.58–1.57)  | 0.854  | 80.10%|              |
| TL groups    |                |                   |        |      | 0.100        |
| 2            | 16             | 1.56 (1.21–2.02)  | 0.001  | 72.00%|              |
| Risk type    |                |                   |        |      | 0.050        |
| RR           | 4              | 0.55 (0.17–1.82)  | 0.330  | 87.60%|              |
| HR           | 14             | 1.69 (1.36–2.11)  | 0.000  | 60.10%|              |
| Total        | 18             | 1.44 (1.10–1.88)  | 0.008  | 75.40%|              |

a: results of subgroups with two or more studies included were presented.

Abbreviations: GC: gastrointestinal cancer, NC: neurologic cancer.

doi:10.1371/journal.pone.0133174.t003
The present meta-analyses of thirty-three independent articles, involving up to 11429 cancer patients for overall survival and 4293 cancer patients for disease progression, identified significant inverse associations between TL and cancer survival outcomes. TL was an independent predictor of prognosis in chronic lymphocytic leukemia, but not in other cancers. This association appeared to be more obvious in older populations, though it was still significant when adjusted for age. As compared with other methods (qPCR and FISH), the application of southern blot resulted in a more robust association. It also seemed that TL in blood cells was a better cancer survival predictor than TL in tumor tissue cells. In addition, large sample sizes and appropriate statistical methods guaranteed a significant association.

Telomeres play a key role in maintenance of cellular senescence and homeostasis. Over the past decades, increasing numbers of studies have observed telomere dysfunction in cancer initiation and development. Telomerase appeared to be repressed in human normal somatic cells but reactivated in cancer cells [50, 51]. Elevated telomerase mRNA expression and telomerase activity in cancer patients both predicted a poor prognosis [52, 53]. In the last few years, several single nucleotide polymorphisms (SNPs) in telomere related key genes have been identified as associated with cancer susceptibility [54–59] and cancer survival [60]. Moreover, Codd et al. showed that SNPs involved in telomere biology were associated with not only mean leukocyte TL but also with risks of several cancers and aging-associated diseases [61]. A hypothesis was that excessive telomere shortening and serious telomere uncapping could trigger DNA damage responses at chromosome ends, which were then recognized as double-strand breaks. Whether dysfunctional telomeres led to cancer or not would depend on the integrity of DNA damage responses [62]. On the other hand, critical telomere shortening was supposed to constitute a driving force for cellular transformation by causing genome instability, thus contributing to tumorigenesis [63]. As an integrated indicator of endogenous and environmental damages, TL was inversely associated with cancer susceptibility based on relevant studies and systematic reviews. Our meta-analysis suggested that TL might serve as a useful cancer prognostic biomarker and a potential therapeutic target for cancer treatment. However, the underlying mechanisms need to be clarified.

Tumorigenesis and progression are complicated processes affected by various genetic and environmental factors [64–67]. Although the present study showed a significant association between short TL and poor cancer prognosis, we still need to draw conclusions with caution based on the stratification results. Short TL may predispose to a number of cancers, but in contrast to the common pattern, longer telomeres were associated with increased risk of certain cancers, such as melanoma [68, 69] and soft tissue sarcoma [70]. Similarly, we found short telomeres predicted poor prognosis in chronic lymphocytic leukemia and colorectal cancer, but reduced death risk in esophagus cancer. Intrinsic biological heterogeneities in different cancers may be a plausible explanation. Distinct biological pathways may be influenced quite differently by TL, resulting in diverse effects on survival of different cancers. However, the number of studies included for each cancer type was far from adequate. To obtain reliable results, more relevant studies are warranted. Age is by far the predominant predictor of individual TL, explaining an estimated 17.5% of the inter-individual variation in leukocyte TL [71]. It is worth considering that TL was significantly related to cancer prognosis in studies which adjusted for age, while no significant evidence was detected in studies without age adjustment. Apparently, not only age, but also many other factors jointly contributed to cancer development and progression. We observed that if a study adjusted for age, it usually adjusted for other confounders at the same time, such as gender, smoking, stage, histology and gene expression. However, the other studies made no adjustments. Therefore, we suspected that in studies without age...
adjustment, other essential confounders might bias the true association. In our meta-analyses, short TL predicted terrible cancer prognosis in patients with older mean age. However, this relationship disappeared in younger patients. Recently Jeon et al. reported a similar result: shorter TL was associated with a significantly poor overall survival and disease-free survival in cancer patients more than 63 years old but not in younger patients [36]. Moreover, Cawthon et al. found telomere shortening in blood contributed to mortality in people aged 60 years or older [72]. We speculated that aged patients were vulnerable and therefore might be more sensitive to fragile telomeres than younger patients. Nevertheless, opposite and indeterminate findings also exist [25, 33]. In Asian and American subjects, significant associations were found for cancer progression, but not for overall cancer survival, while TL was neither associated with overall survival nor with cancer progression in Europeans. Owing to the high heterogeneity within studies of European subjects, it is hard to draw the negative conclusion. Besides, ethnicity might differ from person to person, even if they came from the same country. However, we could not investigate this relationship because there was insufficient information.

Other factors including study design, experimental approach and analysis strategy can also influence the detection of the relationships between TL and cancers. As compared to qPCR, southern blot conferred a modestly stronger effect for both overall cancer survival and progression. Unlike direct measurement such as by southern blot, qPCR evaluate TL using a ratio of telomere/single copy gene (T/S) [73]. This indirect method can’t generate absolute values for TL, and thus may introduce measurement error and bias real effects. TL in blood cells showed a stronger relationship with age compared with TL in other tissues, whether in healthy populations or in cancer patients [72, 74]. Our results were in agreement with this and suggested that leucocyte TL might be a preferential indicator for age-related disease and disease survival. This was exciting because blood is a convenient tissue to collect and yields high-quality DNA which is more suitable for TL assays than that from other tumor or non-tumor tissues. In the great majority of the included studies, telomeres were divided into two groups: a long telomere group and a short telomere group. Although the classification criteria might be different (e.g. median of TL, cut-point from ROC curve or empirical value), our results showed that dichotomizing TL was sufficient to find a significant association. However, association was non-
significant in studies which divided telomeres into three groups. Since only two studies were in this subgroup, we think more studies are needed. In addition, studies with larger sample sizes and estimating risk effects using HRs explained part of the heterogeneity among studies for cancer progression and shared consistent significant associations for overall cancer survival and progression, indicating that well designed large cohort studies are necessary to discover the true associations.

As far as we are aware, this is the first meta-analysis discussing the association between TL and cancer survival. The included articles were all prospective studies, and the records of TL and disease outcomes were considered credible. Our results seemed stable and reliable after performing sensitivity analyses and testing the publication bias. Despite its strengths, some limitations should be acknowledged. Firstly, we failed to find definitive sources of heterogeneity in the studies for cancer overall survival. Discords existed in the results of several subgroups after stratification, for example, TL was significantly associated with cancer overall survival in studies with older mean age, but not in younger patients. However, these discrepancies cannot be the cause of the heterogeneity as there was high heterogeneity among the studies in each subgroup. Although we have identified a partial source of heterogeneity for cancer progression, we could not investigate further due to limited information. Secondly, TLs were measured at a single time point in our included studies. A series of longitudinal TL records might contribute to characterization of the dynamic variation of this association. Lastly, cancer survival was determined by many factors, including cancer stage, pathological pattern, and critically, disease therapy. Only discussing age in our stratification analyses could be considered insufficient. More large scale studies are required to further explore the association and uncover the underlying biological mechanism.

In conclusion, our meta-analyses provided evidence for an inverse association between TL and risk of cancer survival, particularly for chronic lymphocytic leukemia. The association suggested that leucocyte TL might be a predictive biomarker for cancer prognosis in old people. However, our findings need to be updated and confirmed in the future, and additional studies are required to further characterize the nature of this association under different circumstances.

Supporting Information
S1 File. PRISMA checklist: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
(DOC)

S1 Table. Adjusted confounders for each study.
(DOCX)

S2 Table. Results of sensitivity analysis.
(DOCX)

Author Contributions
Conceived and designed the experiments: SH YZ. Performed the experiments: CZ XC. Analyzed the data: CZ XC. Contributed reagents/materials/analysis tools: LL CW. Wrote the paper: CZ.

References
1. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569–573. PMID: 1708110
2. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661–673. PMID: 11572773
3. Huffman KE, Levene SD, Tesmer VM, Shay JW, Wright WE. Telomere shortening is proportional to the size of the G-rich telomeric 3’-overhang. J Biol Chem. 2000; 275: 19719–19722. PMID: 10787419
4. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991; 256: 271–282. PMID: 1722017
5. Martínez P, Biasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11: 161–176. doi: 10.1038/nrc3025 PMID: 21346783
6. Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? Epidemiol Rev. 2013; 35: 112–131. doi: 10.1093/epirev/mxs008 PMID: 23902541
7. Antandl SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641–645. PMID: 10949306
8. Biasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25–34. PMID: 9335332
9. Engelhardt M, Drulinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res. 1997; 3: 1931–1941. PMID: 9815582
10. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866–868. PMID: 2392154
11. Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer 2010; 102: 1300–1305. doi: 10.1038/sbjc.6605644 PMID: 20386541
12. D’Mello MJ, Ross SA, Briel M, Anand SS, Gerstein H, Paré G. Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis. Circ Cardiovasc Genet. 2015; 8: 82–90. doi: 10.1161/CIRCGENETICS.113.000485 PMID: 25406241
13. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014; 349: g4227–g4227. doi: 10.1136/bmj.g4227 PMID: 25006006
14. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1238–1250. doi: 10.1158/1055-9965. EPI-11-0005 PMID: 21467229
15. Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One 2011; 6: e20466. doi: 10.1371/journal.pone.0020466 PMID: 21695195
16. Chen Y, Qu F, He X, Bao G, Liu X, Wan S, et al. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann Oncol. 2014; 25: 869–876. doi: 10.1093/annonc/mdu016 PMID: 24608194
17. Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres A-J, Diaz-Rubio E, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006; 106: 541–551. PMID: 16388518
18. Svensson U, Nordfjall K, Stegmayr B, Tavelin B, et al. Telomere length in peripheral blood cells. Cancer Res. 2008; 68: 3618–3623. doi: 10.1158/1055-9965. EPI-11-0005 PMID: 18483243
19. Duggan C, Risques R, Alfano C, Prunkard D, Imamaya I, Holte S, et al. Change in peripheral blood leukocyte telomere length and mortality in breast cancer survivors. J Natl Cancer Inst. 2014; 106: dju035. doi: 10.1093/jnci/dju035 PMID: 24627273
20. Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 2011; 13: R56. doi: 10.1186/bcr2893 PMID: 21645396
21. Shen J, Gammon MD, Terry MB, Bradshaw PT, Wang Q, Tavelin B, et al. Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival. Breast Cancer Res Treat. 2012; 134: 393–400. doi: 10.1007/s10549-012-2058-9 PMID: 22527105
22. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Health Research Institute. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
23. Zhang D-H, Chen J-Y, Hong C-Q, Yi D-Q, Wang F, Cui W. High-risk human papillomavirus infection associated with telomere elongation in patients with esophageal squamous cell carcinoma with poor prognosis. Cancer 2014; 120: 2673–2683. doi: 10.1002/cncr.28797 PMID: 24840723
24. Yan S, Han B, Wu Y, Zhou D, Zhao Y. Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia. Leuk Lymphoma 2013; 54: 1437–1441. doi: 10.3109/10428194.2012.729834 PMID: 23157242

25. Weischer M, Nordestgaard BG, Crawthon RM, Freiberg JJ, Tybjærg-Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst 2013; 105: 459–468. doi: 10.1093/jnci/djt016 PMID: 23468462

26. Svenson U, Ljungberg B, Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res. 2009; 69: 2896–2901. doi: 10.1158/0008-5472.CAN-08-3513 PMID: 19318563

27. Spanoudakis E, Bzdaiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, et al. Dynamics of telomere's length and telomerase activity in chromosome polymorphic neoplasms. Leuk Res. 2011; 35: 459–464. doi: 10.1016/j.leukres.2010.07.042 PMID: 20828816

28. Russo A, Modica F, Guarerra S, Fiorito G, Pardini B, Viberti C, et al. Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23: 2439–2446. doi: 10.1158/1055-9965.EPI-14-0228 PMID: 25234236

29. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009; 23: 1062–1072. doi: 10.1038/leu.2008.399 PMID: 19340005

30. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukaemia with different biological characteristics and clinical outcomes. Haematologica. 2011; 97: 56–63. doi: 10.3324/haematol.2011.049874 PMID: 21933855

31. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol. 2013; 88: 647–651. doi: 10.1002/ajh.23466 PMID: 23620080

32. Lottschi D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, et al. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in chronic lymphocytic leukaemia patients. Neuropeoncology 2013, 15: 423–432. doi: 10.1093/neuonc/nos299 PMID: 23932925

33. Liu HQ, An JZ, Liu J, Yang JF, Zhang HX, Zhao BY, et al. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 2012; 33: 1040–1045. doi: 10.1093/carcin/bgr998 PMID: 22318909

34. Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, et al. Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev. 2015; 24: 336–343. doi: 10.1158/1055-9965.EPI-14-0992 PMID: 25416716

35. Kotsovolos J, Prescott J, De Vivo I, Fan I, McLaughlin J, Rosen B, et al. Telomere length and mortality following a diagnosis of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23: 2603–2606. doi: 10.1158/1055-9965.EPI-14-0889 PMID: 25189293

36. Jeon H-S, Choi YY, Choi JE, Lee WK, Lee E, Yoo SS, et al. Telomere length of tumor tissues and survival in patients with early stage non-small cell lung cancer. Mol Carcinog. 2014; 53: 272–279. doi: 10.1002/mc.21972 PMID: 23065997

37. Hultdin M, Rosenquist R, Thunberg U, Tobin G, Norrback KF, Johnson A, et al. Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2005; 88: 593–598. PMID:12592375

38. Hepathy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, et al. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013; 3: 1130–1141. doi: 10.1158/2159-9290.CD-13-0135 PMID: 23779129

39. Gertler R, Doll D, Maak M, Feith M, Rosenberg R. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer 2008; 112: 2173–2180. doi: 10.1002/cncr.24919 PMID: 18948304

40. Gertler R. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal cancer. J Clin Oncol. 2004; 22: 1807–1814. PMID: 15143073

41. Borsă M, Cullman I, Norén-Nyström U, Sundström C, Porwit A, Forestier E, et al. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia-associations with immunophenotype and cytogenetic subgroup. Exp Hematol. 2011; 39: 1144–1151. doi: 10.1016/j.exphem.2011.08.014 PMID: 21914494

42. Willett P, Willett J, Kloss-Brandstatter A, Kronenberg F, Kiechl S. Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. JAMA 2011; 306: 42–44. doi: 10.1001/jama.2011.901 PMID: 21730239
43. Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111: 2246–2252. PMID: 18045969

44. Bechter OE, Eisterer W, Pail G, Hilde W, Küh T, Thaler J, et al. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998; 58: 4918–4922. PMID: 9810000

45. Augustin TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, et al. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 2015; 112: 313–318. doi: 10.1038/bjc.2014.561 PMID: 25412235

46. Pezzolo A, Pistorio A, Gambini C, Haupt R, Ferraro M, Emirino G, et al. Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget 2015; 6: 7493–7503. PMID: 25595889

47. Chen Y, Wu Y, Huang X, Qu P, Li G, Jin T, et al. Leukocyte telomere length: a novel biomarker to predict the prognosis of gloma patients. J Cancer Res Clin Oncol. 2015; In press.

48. Qu F, Li R, He X, Li Q, Xie S, Gong L, et al. Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients. Mol Oncol. 2015; 9: 727–739. doi: 10.1016/j.molonc.2014.11.008 PMID: 25515040

49. Boscolo-Rizzo P, Rampazzo E, Perissinotto E, Piano MA, Giungo S, Baboci L, et al. Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncol. 2015; 51: 500–507. doi: 10.1016/j.oraloncology.2015.02.100 PMID: 25771075

50. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–2015. PMID: 7605428

51. Tahara H, Kuniyasu H, Yokozi H, Yasui W, Shby JW, lde T, et al. Telomerase activity in neoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res. 1995; 1: 1245–1251. PMID: 9815918

52. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Mareto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer 2013; 108: 278–284. doi: 10.1038/bjc.2012.602 PMID: 23322193

53. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004; 22: 1807–1814. PMID: 15143073

54. Haiman CA, Chen GK, Vachon CM, Czianz F, Dunning A, Milikan RC, et al. A common variant at the TERT-CLPTM1 locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011; 43: 1210–1214. doi: 10.1038/ng.985 PMID: 22037553

55. Kinnersley B, Migliorini G, Broderick P, Whiffen N, Dobbins SE, Casey G, et al. The TERT variant rs2736100 is associated with colorectal cancer risk. Br J Cancer 2012; 107: 1001–1008. doi: 10.1038/bjc.2012.329 PMID: 22878375

56. McKay JD, Hung RJ, Gabracea V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008; 40: 1404–1406. doi: 10.1038/ng.254 PMID: 18978790

57. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 1q22.1, 1q23.1 and 5p15.33. Nat Genet. 2010; 42: 224–228. doi: 10.1038/ng.522 PMID: 20101243

58. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sansom M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2011; 43: 899–904. doi: 10.1038/ng.407 PMID: 19578367

59. Zhong R, Liu L, Zou L, Zhu Y, Chen W, Zhu B, et al. Genetic variations in TERT-CLPTM1L locus are associated with risk of lung cancer in Chinese population. Mol Carcinog. 2013; 52 Suppl 1: E118–E126. doi: 10.1002/mc.22043 PMID: 23908149

60. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 2013; 110: 17426–17431. doi: 10.1073/pnas.1310522110 PMID: 24101484

61. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013; 45: 422–427, e421–422. doi: 10.1038/ng.2528 PMID: 23535734

62. de Lange T. How telomeres solve the end-protection problem. Science 2009; 326: 948–952. doi: 10.1126/science.1170633 PMID: 19965504

63. Günes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013; 152: 390–393. doi: 10.1016/j.cell.2013.01.010 PMID: 23374336
64. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012; 156: 635–648. doi: 10.7326/0003-4819-156-9-201205010-00006 PMID: 22547473

65. Zhu B, Tian J, Zhong R, Tian Y, Chen W, Qian J, et al. Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population. Mol Carcinog. 2014; In press.

66. Li J, Zou L, Chen W, Zhu B, Shen N, Ke J, et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One 2014; 9: e93437. doi: 10.1371/journal.pone.0093437 PMID: 24691133

67. Zhu B, Zou L, Qi L, Zhong R, Miao X. Allium vegetables and garlic supplements do not reduce risk of colorectal cancer, based on meta-analysis of prospective studies. Clin Gastroenterol Hepatol. 2014; 12: 1991–2001, e1–e4. doi: 10.1016/j.cgh.2014.03.019 PMID: 24681077

68. Burke LS, Hyland PL, Pfeiffer RM, Prescott J, Wheeler W, Mirabello L, et al. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 2013; 8: e71121. doi: 10.1371/journal.pone.0071121 PMID: 23990928

69. Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res. 2011; 71: 6758–6763. doi: 10.1158/0008-5472.CAN-11-1988 PMID: 22028319

70. Xie H, Wu X, Wang S, Chang D, Pollock RE, Lev D, et al. Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. Cancer 2013; 119: 1885–1891. doi: 10.1002/cncr.27984 PMID: 23408253

71. Daniali L, Benetos A, Susser E, Kark JD, Labat C, Kimura M, et al. Telomeres shorten at equivalent rates in somatic tissues of adults. Nat Commun. 2013; 4: 1597. doi: 10.1038/ncomms2602 PMID: 23511462

72. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361: 393–395. PMID: 12573379

73. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2003; 30: e47.

74. Valls-Bautista C, Piñol-Felis C, Reñé-Espinet JM, Buenestad-García J, Viñas-Salas J. In colon cancer, normal colon tissue and blood cells have altered telomere lengths. J Surg Oncol. 2015; 111: 899–904. doi: 10.1002/jso.23894 PMID: 25873347